| Nemaura Medical (NASDAQ: NMRD) Provides Fiscal 2019 Year-End Business Update |
| |
|
Nemaura Medical (NASDAQ: NMRD), a medical technology company commercializing SugarBEAT®, a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, provided a business update for the fiscal year ending March 31, 2019 and reported on recent corporate developments.
Key Highlights:
• Completed pivotal clinical studies for SugarBEAT®
• Received CE Mark approval for SugarBEAT®
• Hired Dr. Fred Schaebsdau, formerly the General Manager of Dexcom Germany, to lead commercialization of SugarBEAT in Europe and global strategic collaborations
• Announced that Nemaura will allow third-party applications, such as diabetes management, exercise and nutrition focused apps royalty free access to SugarBEAT® CGM app data
• Completed two summative human factors usability studies for SugarBEAT® in preparation for submission of De-Novo 510(k) to the U.S. FDA
• Incorporated new predictive alert functionality into SugarBEAT® designed to provide visual indication and alarms when glucose levels are falling or rising above minimum and maximum thresholds
Key Quote: “We have developed a highly differentiated device with distinct advantages over traditional CGMs. As the world’s first non-invasive, needle-free, continuous CGM, the fact that our device sits on the skin, is completely painless, versatile in terms of wear time, and will be the lowest priced CGM in the market, provides us major competitive advantages as we begin commercialization of SugarBEAT in Europe.” – Dr. Faz Chowdhury, CEO
What’s Next: In the United Kingdom, Nemaura’s exclusive Licensee Dallas Burston Ethitronix Ltd., has initiated launch plans drawing off a stock of 12,500 SugarBEAT® transmitters Nemaura ordered in 2018 in anticipation of CE approval, therefore minimizing lead times. This launch will initially encompass post market surveillance and key opinion leader monitoring of SugarBEAT® utility by diabetics and pre-diabetics, the results of which will be presented at Nemaura’s symposia at EASD on the 19th September 2019 in Barcelona. SugarBEAT® is intended to be offered on a phased sale basis, direct to consumers and patients on flexible subscription-based models via a dedicated website. In parallel the company are planning a submission for drug tariff listing to allow SugarBEAT® to be made available on prescription in the United Kingdom.
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.
|
|
| |
|
| Immuron Limited (NASDAQ: IMRN): US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study |
| |
|
Key Highlights:
• Travelan® shigellosis challenge studies in non-human primates successfully completed
• Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals compared to placebo and demonstrated a significant clinical benefit
• Prophylactic administration of Travelan® may provide an effective prevention alternative to antibiotics for gastrointestinal infections in humans
• Three new Shigella specific anti-microbial therapeutics under preclinical evaluation
• A preventative treatment that protects against enteric diseases, specifically Shigella, is a high priority objective for the US Army
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of many gut mediated pathogens, is pleased to provide shareholders with an update on the company’s cooperative research and development agreements with the US Department of Defense (US DoD). Please click here to read more.
The Backstory: Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron’s technology platform utilizes highly specific vaccines for the generation of hyperimmune antibody-rich bovine colostrum, providing a means of antimicrobial therapy without the drawbacks of antibiotics to treat gut-mediated diseases. The Company currently markets Travelan®, which is a listed medicine on the Australian Register for Therapeutic Goods, in Australia to reduce the risk of travelers’ diarrhea.
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
|
|
| |
|
| MYnd Analytics (NASDAQ: MYND) and Emmaus Life Sciences Announce Availability of Definitive Joint Proxy Statement/Prospectus Relating to Merger and Spinoff Transaction |
| |
|
MYnd Analytics (NASDAQ: MYND), a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, and Emmaus Life Sciencesn (“Emmaus”), a leader in sickle cell disease treatment, announced today that the registration statement filed with the Securities and Exchange Commission (SEC), which includes the definitive joint proxy statement/prospectus of MYnd and Emmaus, was declared effective by the SEC on June 11, and companies intend to commence mailing to their stockholders on June 14. The respective special stockholder meetings will be held on July 9, 2019 to consider approval of the proposed merger and spin-off transaction announced in January of this year. The record date for each meeting is June 7, 2019.
The Backstory: MYnd Analytics (www.myndanalytics.com), with its wholly owned subsidiary Arcadian Telepsychiatry Services, LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues. The MYnd Psychiatric EEG Evaluation Registry (PEER) is a predictive analytics decision support tool that helps physicians reduce trial and error treatment for behavioral health conditions. PEER provides the physician a personalized care plan with recommended treatment options based on a patient’s unique brain markers, reducing treatment time and treatment costs. Arcadian Telepsychiatry Services, LLC provides a suite of complementary telemedicine services that can be combined with PEER, including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. MYnd’s customers include major health plans, health systems, and community-based organizations. To read more about the benefits of this patented technology for patients, physicians and payers, please visit: www.myndanalytics.com.
Disclosure
MYnd Analytics (NASDAQ: MYND) is a client of RedChip Companies, Inc. MYND agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services.
|
|
| |
|
| Emerald Health Therapeutics (OTCQX: EMHTF) Contract for 1200 Acres of Canadian Hemp Harvest |
| |
|
Emerald Health Therapeutics (OTCQX: EMHTF) expanded its agreement to purchase harvested hemp flower and leaf, or hemp chaff, from Emerald Health Hemp (“EHH”) from 1,000 to 1,200 acres for 2019. EHH is a wholly owned subsidiary of Emerald Health Sciences and a related party of Emerald.
Why It Matters: Based on last year’s harvest, Emerald expects production from the 1,200 acres to be at least 270,000 kg of hemp chaff in 2019 with, conservatively, approximately 2% cannabidiol (“CBD”) content. Emerald estimates that this hemp may yield 3,500 kg of extracted CBD, which it plans to use to manufacture premium oils, softgels and associated value-added products for Canadian adult-use and medical consumers.
Key Quote: “Emerald, through its partnership with the Factors Group and their scalable processing capacity, is uniquely situated to become one of Canada’s leading producers of premium CBD products from hemp. We established our first-mover advantage in 2018 by securing hemp on a large scale and gaining production insights that will benefit us in 2019. With even more supply contracted for this year, we expect significant near-term growth in this market segment.” - Dr. Avtar Dhillon, President and Executive Chairman
The Backstory: Emerald Health is a Canadian licensed producer of cannabis. Emerald has secured exclusive strategic partnerships for large scale extraction and softgel encapsulation, as well as for proprietary technology to enhance cannabinoid bioavailability. Its team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Learn more in our exclusive interview with Emerald’s CFO Rob Hill: youtu.be/XnDWHv4BXmE.
|
|
| |
|
| eSports Entertainment (OTCQB: GMBL) Partners with Dignitas to Provide P2P Esports Betting |
| |
|
eSports Entertainment Group (OTCQB: GMBL) a licensed online gambling company with a specific focus on esports wagering and 18+ gaming, is pleased to announce a multi-year partnership with Harris Blitzer Sports & Entertainment (“HBSE”) to provide safe and transparent P2P esports betting to Dignitas fans via VIE.gg.
Why It Matters: Dignitas is an international esports team with one of the most iconic and recognizable brands in the professional gaming industry that fields teams in seven of esports' largest and most popular games. Dignitas is the esports organization of HBSE, a globally renowned sports and entertainment company whose portfolio includes the Philadelphia 76ers, New Jersey Devils, Crystal Palace F.C. and the Prudential Center, one of the world’s top-ranked venues located in Newark, N.J. HBSE is owned by an investor group led by Managing Partners Josh Harris, the Co-Founder and Senior Managing Director of Apollo Global Management, LLC., as well as, David Blitzer, the Global Head of Blackstone’s Tactical Opportunities group.
Key Quote: “I am very proud of this new partnership with HBSE and their Dignitas esports brand, which is founded in our shared common beliefs of player safety above all else. I look forward to sharing our incredible product with Dignitas’ highly engaged fan base over the next three years and beyond. For Esports Entertainment Group, a partnership of this caliber is a significant milestone for our shareholders and tremendous validation of both our P2P esports wagering model and future plans within the esports world.” - Grant Johnson, CEO
The Backstory: Esports Entertainment Group is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers bet exchange style wagering on esports events in a licensed, regulated and secure platform to the global esports audience at vie.gg. In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multi-player mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports.
Disclosure
Esports Entertainment Group, Inc. (GMBL) is a client of RedChip Companies, Inc. GMBL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.
|
|
| |
|
| Advantego (OTC: ADGO) Retains Hooray Agency to Brand ADGO |
| |
|
Advantego Corporation (OTC: ADGO) today announced the retention of Hooray Agency, headquartered in Irvine, CA (formerly Hyperdisk Marketing) – an award-winning marketing partner for global luxury brands – to provide branding, marketing and creative content to Advantego for all of its ADGO products, services and customers.
Key Quote: “This is the culmination of many months of looking for the right fit that could deliver the ‘WOW’ factor from a marketing perspective.” Robert W. (Rob) Ferguson, CEO of Advantego
The Backstory: Advantego Corporation (ADGO) is a business solutions provider that develops stand-alone digital delivery systems, electronic and enterprise software products to capitalize on niche opportunities within a specific market. The Company leverages a proprietary Intelligent Solution Platform, combining leading third-party, cutting-edge technologies with existing data and systems to deliver a turnkey specialized Business Process as a Service (BPaaS) that is both scalable and cost-effective. The Company offers a variety of stand-alone products and services tailored specifically to targeted industries, combining these with multiple software applications for large enterprises, affiliate networks and franchise operators as comprehensive, managed bundled solutions. The Company’s services also include product design, engineering and OEM manufacturing of hardware products. In addition, it licenses and distributes third-party proprietary software and hardware from a host of Strategic Partners. Website: www.advantego.com. Twitter: @Advantego.
Disclosure
Advantego Corporation (OTCQB: ADGO) is a client of RedChip Companies. Advantego Corporation (OTCQB: ADGO) pays RedChip a monthly cash fee for investor awareness services.
|
|
| |
|
| |
| Quote of the Week |
| |
"It’s harder and always takes longer than you anticipate."
-Manny Villafana, Founder of St. Jude Medical |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
